Table 2.
| ||
---|---|---|
MEDIAN (IQR) OR N (%) | ||
| ||
Age (years) | 55.00 (35.00–68.00) | |
| ||
Lymphocyte (103/μL) | 1.37 (1.01–1.93) | |
| ||
D-dimer (ng/mL) | 394.00 (199.25–1017.50) | |
| ||
C reactive protein (mg/L) | 23.90 (6.00–75.20) | |
| ||
Fibrinogen (mg/dL) | 487.00 (366.00–614.00) | |
| ||
Ferritin (ng/mL) | 166.34 (76.51–403.04) | |
| ||
Lactate dehydrogenase (U/L) | 402.00 (324.00–546.00) | |
| ||
Gender | Male | 563 (62.9) |
| ||
Female | 332 (37.1) | |
| ||
Diabetes Mellitus | 172 (19.2) | |
| ||
Hypertension | 283 (31.6) | |
| ||
Heart Failure | 45 (5.0) | |
| ||
Cardiovascular disease | 106 (11.8) | |
| ||
Chronic kidney disease | 28 (3.1) | |
| ||
Chronic obstructive pulmonary disease | 61 (6.8) | |
| ||
Asthma | 39 (4.4) | |
| ||
Other Pulmonary Disease | 11 (1.2) | |
| ||
Cancer | 37 (4.1) | |
| ||
Stroke | 26 (2.9) | |
| ||
Hydroxycloroquine | 854 (95.4) | |
| ||
Favipravir | 238 (26.6) | |
| ||
Azithromycin | 645 (72.1) | |
| ||
Convalescent plasma | 21 (2.39) | |
| ||
Lopinavir/ritonavir | 63 (7.0) | |
| ||
Tocilizumab | 24 (2.7) | |
| ||
Corticosteroid | 50 (5.6) | |
| ||
SARS CoV-2 PCR | Negative | 434 (48.5) |
| ||
Positive | 461 (51.5) | |
| ||
Chest CT | Negative | 262 (29.3) |
| ||
Positive | 633 (70.7) | |
| ||
CO-RADS | 1 | 188 (21.0) |
| ||
2 | 74 (8.3) | |
| ||
3 | 87 (9.7) | |
| ||
4 | 101 (11.3) | |
| ||
5 | 445 (49.7) | |
| ||
PCR and CT | PCR:– and CT:– | 112 (12.5) |
| ||
PCR:+ and CT:– | 150 (16.8) | |
| ||
PCR:- and CT:+ | 322 (36.0) | |
| ||
PCR:+ and CT:+ | 311 (34.7) | |
| ||
Mortality | 84 (9.4) | |
| ||
Need for ICU | 135 (15.1) | |
| ||
Need for IMV in ICU | 92 (68.7) | |
|
IQR: Interquartile Range, PCR: Polymerase Chain Reaction, CT: Computerized Tomography, CO-RADS: COVID-19 Reporting and Data System, ICU: Intensive care unit, IMV: Invasive mechanical ventilation.